Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer by Turner, Nicholas C et al.
The new england  
journal of medicine
n engl j med 373;3 nejm.org July 16, 2015 209
established in 1812 July 16, 2015 vol. 373 no. 3
From Royal Marsden Hospital, London 
(N.C.T.); National Cancer Center, Goyang-si, 
South Korea (J.R.); Institut Gustave Roussy, 
Villejuif, France (F.A.); Peter MacCallum 
Cancer Centre, University of Melbourne, 
Melbourne, VIC, Australia (S. Loi); Sunny-
brook Odette Cancer Centre, Toronto 
(S.V.); Aichi Cancer Center Hospital, Na-
goya, Japan (H.I.); Brustzentrum der 
 Universität München, Munich (N.H.), 
and German Breast Group Forschungs, 
Neu-Isenburg (S. Loibl) — both in Ger-
many; Pfizer, New York (C.H.B., M.K.), La 
Jolla, CA (K.Z., S.R.), and Milan (C.G.); 
and Thomas Jefferson University, Phila-
delphia (M.C.). Address reprint requests 
to Dr. Turner at the Royal Marsden Hos-
pital and Institute of Cancer Research, 
Fulham Rd., London SW3 6JJ, United King-
dom, or at  nicholas . turner@ icr . ac . uk.
This article was published on June 1, 2015, 
at NEJM.org.
N Engl J Med 2015;373:209-19.
DOI: 10.1056/NEJMoa1505270
Copyright © 2015 Massachusetts Medical Society.
BACKGROUND
Growth of hormone-receptor–positive breast cancer is dependent on cyclin-depen-
dent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 
phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an 
inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.
METHODS
This phase 3 study involved 521 patients with advanced hormone-receptor–posi-
tive, human epidermal growth factor receptor 2–negative breast cancer that had 
relapsed or progressed during prior endocrine therapy. We randomly assigned 
patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulves-
trant. Premenopausal or perimenopausal women also received goserelin. The pri-
mary end point was investigator-assessed progression-free survival. Secondary end 
points included overall survival, objective response, rate of clinical benefit, patient-
reported outcomes, and safety. A preplanned interim analysis was performed by 
an independent data and safety monitoring committee after 195 events of disease 
progression or death had occurred.
RESULTS
The median progression-free survival was 9.2 months (95% confidence interval 
[CI], 7.5 to not estimable) with palbociclib–fulvestrant and 3.8 months (95% CI, 
3.5 to 5.5) with placebo–fulvestrant (hazard ratio for disease progression or death, 
0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events 
in the palbociclib–fulvestrant group were neutropenia (62.0%, vs. 0.6% in the 
placebo–fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), 
thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia 
was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated 
patients. The rate of discontinuation due to adverse events was 2.6% with palbo-
ciclib and 1.7% with placebo.
CONCLUSIONS
Among patients with hormone-receptor–positive metastatic breast cancer who had 
progression of disease during prior endocrine therapy, palbociclib combined with 
fulvestrant resulted in longer progression-free survival than fulvestrant alone. 
(Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.)
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A pproximately 80% of breast cancers express estrogen receptors, progesterone receptors, or both. Endocrine therapies 
are the mainstay of treatment for these hormone-
receptor–positive cancers, substantially reducing 
the relapse rate after presentation with early-stage 
cancer.1 Despite advances in endocrine therapy, 
many women have a relapse during or after com-
pleting adjuvant therapy. The care of these 
women remains a considerable clinical chal-
lenge. Single-agent treatment with an aromatase 
inhibitor or tamoxifen has shown limited clini-
cal benefit.2,3 The selective estrogen-receptor 
degrader fulvestrant has modest activity in this 
population of patients,4,5 and the development of 
effective therapies that can reverse resistance to 
endocrine therapy is of clinical importance.
Cyclin-dependent kinases 4 and 6 (CDK4 and 
CDK6), which are activated by D-type cyclins, 
promote cell-cycle entry by phosphorylating Rb 
(retinoblastoma protein), among other proteins, 
to initiate transition from the G1 phase to the 
S phase.6 Multiple oncogenic signals in hormone-
receptor–positive breast cancer converge to pro-
mote expression of cyclin D1 and activation of 
CDK4 and CDK6 to drive breast-cancer prolifera-
tion.7,8 In vitro evidence suggests that breast 
cancer that has developed resistance to prior 
endocrine therapy remains dependent on cyclin 
D1–CDK4 to promote proliferation.9,10
Palbociclib (Ibrance, Pfizer) is an orally bio-
available small-molecule inhibitor of CDK4 and 
CDK6, with a high level of selectivity for CDK4 
and CDK6 over other cyclin-dependent kinases.11 
Palbociclib inhibits CDK4 and CDK6 in vitro, 
resulting in loss of RB1 phosphorylation. It has 
high activity in hormone-receptor–positive breast-
cancer cell lines and is synergistic in combina-
tion with endocrine therapies.12 Prior phase 2 
research suggested that single-agent palbociclib 
induced responses in hormone-receptor–positive 
breast cancer.13 In an open-label, randomized, 
phase 2 study involving patients with newly diag-
nosed metastatic estrogen-receptor–positive breast 
cancer, palbociclib in combination with letrozole 
was associated with significantly longer progres-
sion-free survival than was letrozole alone.14 The 
PALOMA3 trial assessed the safety and efficacy 
of the combination of palbociclib and fulvestrant 
in premenopausal or postmenopausal women 
with hormone-receptor–positive advanced breast 
cancer that progressed during prior endocrine 
therapy.
Me thods
Patients
Women with hormone-receptor–positive, human 
epidermal growth factor receptor 2 (HER2)–
negative advanced breast cancer were eligible if 
their cancer had relapsed or progressed during 
prior endocrine therapy. Hormone-receptor sta-
tus (expression of estrogen receptor, progesterone 
receptor, or both) and HER2 status were as-
sessed locally with the tumor tissue obtained 
most recently. Women were eligible regardless of 
menopausal status; those with postmenopausal 
breast cancer must have had disease progression 
during prior aromatase inhibitor therapy, de-
fined as progression during or within 1 month 
after the end of therapy in the context of meta-
static disease or progression during or within 12 
months after the completion or discontinuation 
of adjuvant therapy. Women with premenopausal 
or perimenopausal breast cancer must have had 
disease progression during prior endocrine 
therapy, defined as progression during or within 
1 month after the end of prior endocrine therapy 
in the context of metastatic disease or progres-
sion during or within 12 months after discon-
tinuation of adjuvant tamoxifen. Eligible patients 
were allowed one prior line of chemotherapy in 
the context of advanced disease. The qualifying 
endocrine therapy was not required to be the 
most recent treatment before randomization, but 
progression during the immediate prior therapy 
was required for randomization.
Patients had measurable disease according to 
Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1,15 or bone-only lytic or 
mixed lytic and blastic lesions that could be 
accurately assessed by means of computed to-
mography (CT) or magnetic resonance imaging 
(MRI). Patients had adequate organ function and 
an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1 (on a scale of 0 to 
5, with 0 indicating no symptoms, 1 indicating 
mild symptoms, and higher numbers indicating 
increasing degrees of disability). Prior exposure 
to fulvestrant or everolimus was not allowed, 
and patients with uncontrolled brain metastases 
or symptomatic visceral spread who were at risk 
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for life-threatening complications were excluded. 
Women were defined as postmenopausal if they 
were at least 60 years of age, had undergone 
bilateral oophorectomy, or were younger than 
60 years of age and had had cessation of regular 
menses for at least 12 consecutive months with 
no alternative pathologic or physiological cause 
and had serum levels of estradiol and follicle-
stimulating hormone in the postmenopausal 
range. All other patients were designated as be-
ing premenopausal or perimenopausal.
Study Design
In this double-blind, phase 3 study, patients 
were randomly assigned in a 2:1 ratio to receive 
palbociclib (125 mg per day orally for 3 weeks, 
followed by 1 week off) and fulvestrant (500 mg 
intramuscularly per standard of care every 14 days 
for the first three injections and then every 
28 days) or matching placebo and fulvestrant. 
Premenopausal or perimenopausal patients re-
ceived goserelin for the duration of study treat-
ment, starting at least 4 weeks before randomiza-
tion and continuing every 28 days. Randomization 
was stratified according to the presence or ab-
sence of visceral metastasis, menopausal status 
at study entry (postmenopausal vs. premeno-
pausal or perimenopausal), and sensitivity to 
prior endocrine therapy. Patients were defined as 
sensitive to prior endocrine therapy if they had a 
relapse after 24 months of adjuvant endocrine 
therapy or had a clinical benefit (objective re-
sponse [complete or partial] or stable disease 
lasting ≥24 weeks) from prior endocrine therapy 
in the context of advanced disease.
Treatment continued until objective demon-
stration of disease progression, unacceptable 
toxic effects, or withdrawal of consent. Crossover 
in the event of disease progression was not al-
lowed. Reduction in the daily dose of palbociclib 
or placebo owing to adverse events was allowed 
in stages (to 100 mg, then 75 mg, and then 75 mg 
on a schedule of 2 weeks on and 2 weeks off), 
with criteria defined in the study protocol (for 
dose-modification guidelines, see Table S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org; the protocol is 
also available at NEJM.org). Reduction in the 
dose of fulvestrant was not allowed. Starting a 
new cycle of palbociclib or placebo was delayed 
until a reduction in the severity of adverse events 
to grade 2 or lower. If palbociclib or placebo was 
delayed, fulvestrant and goserelin were contin-
ued on the preplanned schedule.
One cycle was defined as 3 weeks on, fol-
lowed by 1 week off (palbociclib or placebo). All 
patients had to provide tumor samples from a 
biopsy of a recurrent breast cancer (although 
patients with bone-only disease could provide 
archival tissue) and blood samples (including 
samples for analysis of circulating tumor DNA) 
for future translational research.
Procedures
Imaging (CT, MRI, or both) was performed at 
screening within 4 weeks before randomization, 
then repeated every 8±1 weeks until disease pro-
gression. Radiographic bone scans were performed 
at screening and subsequently as clinically indi-
cated or to confirm complete response. Patients 
who discontinued study drugs without progression 
continued to have scans every 8 weeks. Bio-
chemical and hematologic laboratory tests were 
performed on days 1 and 15 of the first two 
cycles and then on day 1 of subsequent cycles. 
Vital signs were assessed on day 1 of every cycle; 
adverse events were recorded and graded accord-
ing to the National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 
4.0, with relationship to study medications re-
corded.
End Points
The primary end point was investigator-assessed 
progression-free survival according to RECIST, 
version 1.1.15 Secondary end points included 
overall survival; survival probability at 1, 2, and 
3 years; objective response; duration of response; 
rate of clinical benefit; patient-reported out-
comes; pharmacokinetics; and safety. Patient-
reported outcome end points included health-
related quality-of-life scores on the EuroQol 
Group 5-Dimension Self-Report Questionnaire 
(EQ-5D), the European Organisation for Research 
and Treatment of Cancer (EORTC) Quality of 
Life Core Module (QLQ-C30), and the EORTC 
Breast Cancer Module (QLQ-BR23).
Study Oversight
The PALOMA3 study was designed by an aca-
demic steering group, including representatives 
from the sponsor (Pfizer). All the authors con-
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firm that the study conformed to the protocol 
and vouch for the accuracy and completeness of 
the data. The first draft of the manuscript was 
prepared by the first and last authors and repre-
sentatives of the sponsor. Subsequently, all the 
authors were involved with interpretation of the 
data and in writing and reviewing the manu-
script. A professional medical writer paid by the 
sponsor provided editorial assistance with incor-
poration of the authors’ revisions into the manu-
script. Fulvestrant was provided by AstraZeneca.
The study was approved by an institutional 
review board, or equivalent, at each site, and all 
the patients gave written informed consent be-
fore enrollment. The study was conducted ac-
cording to the principles of Good Clinical Prac-
tice and the Declaration of Helsinki. A steering 
committee reviewed the study conduct. An inde-
pendent data and safety monitoring committee 
met every 6 months to review safety and pharma-
cokinetics and to perform the interim analysis.
Statistical Analysis
The primary end point of progression-free sur-
vival was assessed with the use of a predefined 
log-rank test stratified according to the presence 
or absence of visceral disease and sensitivity to 
prior endocrine therapy. We estimated that 238 
events of progression or death would be re-
quired in the two treatment groups for the study 
to have 90% power to detect a hazard ratio of 
0.64 (representing a 56% improvement in medi-
an progression-free survival [6.00 months vs. 
9.38 months]) with a one-sided significance 
level of α = 0.025. A total sample of 417 patients 
was to be enrolled. One interim analysis was 
planned for early stopping of the study owing to 
efficacy after approximately 60% of the total 
progression-free survival events were observed 
with the use of a prespecified Haybittle–Peto ef-
ficacy boundary (α = 0.00135).16 The information 
fraction of the interim analysis was increased, 
reflecting rapid study enrollment (Fig. S1 in the 
Supplementary Appendix). Central assessment of 
progression-free survival was performed with 
the use of an audit approach involving a random-
sample–based, blinded, independent central re-
view to provide assurance that the investigator-
assessed primary end point was accurate.17 A 
third-party core imaging laboratory performed 
the blinded review for a randomly selected sub-
group of patients (approximately 40%) selected 
after enrollment completion. All reported P val-
ues were two-sided.
R esult s
Patient Clinical and Pathological Features
Between October 7, 2013, and August 26, 2014, 
a total of 521 patients from 144 centers in 17 
countries were randomly assigned to palbociclib 
and fulvestrant (347 patients) or placebo and 
fulvestrant (174 patients) (Fig. S2 in the Supple-
mentary Appendix). Baseline characteristics of 
the intention-to-treat population were well bal-
anced between the study groups (Table 1). The 
median age was 57 years, 59.7% of the patients 
had visceral disease, 79.3% were postmeno-
pausal, and 78.7% had cancers that were sensi-
tive to prior endocrine therapy. All patients had 
HER2-negative disease, 67.0% had both estro-
gen-receptor–positive and progesterone-recep-
tor–positive disease, and 26.7% had estrogen-
receptor–positive but progesterone-receptor–
negative disease. A total of 77.9% of the patients 
had measurable disease, and 23.2% had at least 
partially lytic bone-only disease. Overall, 122 
patients (23.4%) presented with metastatic dis-
ease as the initial disease manifestation (86 pa-
tients [24.8%] in the palbociclib–fulvestrant 
group and 36 patients [20.7%] in the placebo–
fulvestrant group).
Study Treatment
By the data cutoff date (December 5, 2014) for 
the interim analysis, 195 events of disease pro-
gression or death had occurred (102 events in 
the palbociclib–fulvestrant group and 93 in the 
placebo–fulvestrant group with 2:1 randomiza-
tion); 238 patients (68.6%) continue to receive 
treatment with palbociclib–fulvestrant and 75 
patients (43.1%) with placebo–fulvestrant. The 
median relative dose intensity was 91.7% for 
palbociclib and 99.7% for fulvestrant in the pal-
bociclib–fulvestrant group and 100% for both 
placebo and fulvestrant in the placebo–fulves-
trant group. The palbociclib dose was reduced in 
109 of 345 patients (31.6%), whereas the placebo 
dose was reduced in 3 of 172 patients (1.7%). 
The main reason for study-treatment discontinu-
ation was disease progression, occurring in 85 
patients (24.5%) assigned to palbociclib–fulves-
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trant and 87 patients (50.0%) assigned to placebo–
fulvestrant. Discontinuation of palbociclib or 
matching placebo owing to adverse events oc-
curred in 9 patients (2.6%) receiving palbociclib 
and 3 patients (1.7%) receiving placebo.
Adverse Events
The most common adverse events reported for 
the palbociclib–fulvestrant group were neutrope-
nia, leukopenia, fatigue, and nausea (Table 2). 
Hematologic adverse events were frequent in the 
palbociclib–fulvestrant group. Neutropenia (any 
grade) occurred in 78.8% of the patients receiv-
ing palbociclib–fulvestrant versus 3.5% of the 
patients receiving placebo–fulvestrant, leukope-
nia in 45.5% versus 4.1%, anemia in 26.1% ver-
sus 9.9%, and thrombocytopenia in 19.4% ver-
sus 0%. Grade 3 or 4 neutropenia occurred in 
62.0% of the patients receiving palbociclib–ful-
vestrant versus 0.6% of the patients receiving 
placebo–fulvestrant, leukopenia in 25.2% versus 
0.6%, anemia in 2.6% versus 1.7%, and throm-
bocytopenia in 2.3% versus 0%. Rates of febrile 
neutropenia were low, occurring in two patients 
(0.6%) receiving palbociclib–fulvestrant and one 
patient (0.6%) receiving placebo–fulvestrant.
The most common nonhematologic adverse 
events were fatigue (38.0% in the palbociclib–
fulvestrant group vs. 26.7% in the placebo–ful-
vestrant group), nausea (29.0% vs. 26.2%), and 
headache (21.2% vs. 17.4%). A higher incidence 
of infections was reported in the palbociclib–
fulvestrant group than in the placebo–fulves-
trant group (34.2% vs. 24.4%); infections were 
primarily of grade 1 or 2 severity (32.4% vs. 
22.7%). The most common infections were up-
per respiratory infections (19.4% vs. 16.3%). No 
grade 3 or 4 nonhematologic adverse events oc-
curred in more than 2% of the patients receiving 
palbociclib.
Serious adverse events (any cause) occurred in 
9.6% of the patients in the palbociclib–fulves-
trant group and 14.0% of the patients in the 
placebo–fulvestrant group. No individual serious 
adverse event occurred in more than 1% of the 
patients receiving palbociclib. Three patients 
(0.9%) receiving palbociclib and one patient 
(0.6%) receiving placebo had pyrexia, and three 
patients (0.9%) receiving palbociclib and no pa-
tients receiving placebo had a pulmonary embo-
lism. During the study-treatment period, there 
were four deaths in the palbociclib–fulvestrant 
group (all due to disease progression) and two 
deaths in the placebo–fulvestrant group (one due 
to disease progression and one due to intracere-
bral hemorrhage).
Global quality of life was generally main-
tained with palbociclib–fulvestrant but deterio-
rated significantly with placebo–fulvestrant 
(mean overall change from baseline in QLQ-C30 
score [range, 0 to 100, with higher scores indi-
cating a higher quality of life], −0.9 points vs. 
−4.0 points; P = 0.03). Patients receiving palboci-
clib showed a significant improvement from 
baseline in emotional functioning as compared 
with patients receiving placebo (mean overall 
change from baseline score on the emotional-
functioning subscale of the QLQ-C30 scale 
[range, 0 to 100, with higher scores indicating 
better emotional functioning], 2.7 points vs. 
−1.9 points; P = 0.002).
Efficacy of Palbociclib in Combination  
with Fulvestrant
The trial met its primary end point at the inter-
im analysis on the basis of the recommendation 
by the independent data and safety monitoring 
committee. The median progression-free sur-
vival was 9.2 months (95% confidence interval 
[CI], 7.5 to not estimable) with palbociclib–ful-
vestrant and 3.8 months (95% CI, 3.5 to 5.5) 
with placebo–fulvestrant (hazard ratio for dis-
ease progression or death, 0.42; 95% CI, 0.32 to 
0.56; P<0.001) (Fig. 1A). Approximately 40% of 
the patients (211) were randomly selected for 
central imaging assessment by blinded indepen-
dent review. The results of the blinded audit 
were consistent with the investigator-assessed 
primary end point; the median progression-free 
survival was not estimable with palbociclib–ful-
vestrant and was 3.7 months (95% CI, 3.4 to 7.2) 
with placebo–fulvestrant (hazard ratio for dis-
ease progression or death, 0.27; 95% CI, 0.16 to 
0.46; P<0.001) (Fig. 1B).
Subgroup analyses of progression-free sur-
vival according to stratification factors and de-
mographic or prognostic factors revealed consis-
tent results (Fig. 2). In particular, the relative 
difference in progression-free survival between 
palbociclib and placebo was similar in premeno-
pausal or perimenopausal patients and post-
menopausal patients (hazard ratio for disease 
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Characteristic
Palbociclib–Fulvestrant 
(N = 347)
Placebo–Fulvestrant 
(N = 174)
Age
Median — yr 57 56
Range — yr 30–88 29–80
<65 yr — no. (%) 261 (75.2) 131 (75.3)
≥65 yr — no. (%) 86 (24.8) 43 (24.7)
Race — no. (%)†
White 252 (72.6) 133 (76.4)
Asian 74 (21.3) 31 (17.8)
Black or other 20 (5.8) 9 (5.2)
Hormone-receptor status — no. (%)
ER-positive and PR-positive 238 (68.6) 111 (63.8)
ER-positive and PR-negative 91 (26.2) 48 (27.6)
ECOG performance status — no. (%)‡
0 207 (59.7) 115 (66.1)
1 140 (40.3) 59 (33.9)
Disease-free interval§
Median — mo 48 51
≤24 mo — no./total no. (%) 42/235 (17.9) 23/124 (18.5)
>24 mo — no./total no. (%) 186/235 (79.1) 95/124 (76.6)
Menopausal status at study entry — no. (%)
Premenopausal or perimenopausal 72 (20.7) 36 (20.7)
Postmenopausal 275 (79.3) 138 (79.3)
Documented sensitivity to prior hormonal 
therapy — no. (%)¶
Yes 274 (79.0) 136 (78.2)
No 73 (21.0) 38 (21.8)
Visceral metastasis — no. (%)‖ 206 (59.4) 105 (60.3)
Measurable disease — no. (%) 268 (77.2) 138 (79.3)
Disease stage at study entry — no. (%)**
Recurrent locally advanced†† 49 (14.1) 25 (14.4)
Metastatic 296 (85.3) 146 (83.9)
No. of disease sites — no. of patients (%)‡‡
1 111 (32.0) 60 (34.5)
2 99 (28.5) 50 (28.7)
≥3 135 (38.9) 62 (35.6)
Prior endocrine therapy — no. (%)§§
Aromatase inhibitor with or without GnRH 
agonist
296 (85.3) 151 (86.8)
Tamoxifen with or without GnRH agonist 211 (60.8) 104 (59.8)
Most recent therapy — no. (%)
Aromatase inhibitor with or without GnRH 
agonist
238 (68.6) 118 (67.8)
Tamoxifen with or without GnRH agonist 63 (18.2) 30 (17.2)
Table 1. Clinical and Pathological Characteristics of the Patients.*
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progression or death, 0.44 and 0.41, respectively; 
P = 0.94 for interaction between the study-drug 
assignment and menopausal status). Rates of 
overall objective response were 10.4% (95% CI, 
7.4 to 14.1) with palbociclib–fulvestrant and 
6.3% (95% CI, 3.2 to 11.0) with placebo–fulves-
trant (P = 0.16). By the data cutoff date, 31.7% of 
the patients (35.7% of those in the palbociclib–
fulvestrant group and 23.6% of those in the 
placebo–fulvestrant group) continued to receive 
study treatment with less than 24 weeks of fol-
low-up; the median duration of follow-up was 
5.6 months. The rate of clinical benefit (re-
sponse or prolonged stable disease) at the in-
terim analysis was 34.0% (95% CI, 29.0 to 39.3) 
with palbociclib–fulvestrant and 19.0% (95% CI, 
13.4 to 25.6) with placebo–fulvestrant (P<0.001). 
At the time of the interim analysis, data on over-
all survival were immature, with a total of 28 
deaths: 19 patients (5.5%) in the palbociclib–ful-
vestrant group and 9 (5.2%) in the placebo–ful-
vestrant group. Double blinding has been main-
tained after the interim analysis to allow ongoing 
follow-up of overall survival.
Discussion
This double-blind, phase 3, randomized study 
showed that adding palbociclib to fulvestrant 
resulted in substantially longer progression-free 
survival than fulvestrant alone in patients with 
advanced hormone-receptor–positive, HER2-
negative breast cancer that had progressed dur-
ing prior endocrine therapy, irrespective of 
menopausal status. Adverse events observed 
with palbociclib and fulvestrant were consistent 
with previously reported data, and a high rate of 
hematologic adverse events was observed in the 
palbociclib group. Overall, palbociclib main-
tained quality of life, and the rate of discontinu-
ation due to adverse events was similar to that 
observed with placebo.
The findings of this study are consistent with 
prior results with palbociclib in different set-
Characteristic
Palbociclib–Fulvestrant 
(N = 347)
Placebo–Fulvestrant 
(N = 174)
Prior chemotherapy — no. (%)
Neoadjuvant or adjuvant treatment only¶¶ 144 (41.5) 75 (43.1)
Metastatic treatment, with or without prior 
neoadjuvant or adjuvant therapy
107 (30.8) 63 (36.2)
Prior lines of therapy in the context of metastatic 
disease — no. of patients (%)
0 84 (24.2) 45 (25.9)
1 132 (38.0) 70 (40.2)
2 90 (25.9) 43 (24.7)
≥3 41 (11.8) 16 (9.2)
*  No significant differences in the clinical and pathological characteristics of the patients were identified between the 
two treatment groups. ER denotes estrogen receptor, GnRH gonadotropin-releasing hormone, and PR progesterone 
receptor.
†  Race was self-reported. Race was unspecified in one patient in each treatment group.
‡  Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale of 0 to 5, with 0 indicating no 
symptoms, 1 indicating mild symptoms, and higher numbers indicating increasing degrees of disability.
§  The disease-free interval was defined as the time from diagnosis of primary breast cancer to first relapse in patients 
who received adjuvant therapy.
¶  Patients were defined as having sensitivity to prior endocrine therapy if they had a relapse after 24 months of adju-
vant endocrine therapy or had a clinical benefit (objective response [complete or partial] or stable disease lasting  
≥24 weeks) from prior endocrine therapy in the context of advanced disease.
‖  Visceral metastasis was defined as lung, liver, brain, pleural, or peritoneal involvement.
**  Data on disease stage at study entry were missing or unknown for five patients (two in the palbociclib–fulvestrant 
group and three in the placebo–fulvestrant group).
††  Recurrent locally advanced disease included local and regional recurrences.
‡‡  Data on number of disease sites were missing for four patients (two in each treatment group).
§§  Prior endocrine therapy was defined as any endocrine therapy anytime before study entry.
¶¶  These patients did not receive chemotherapy in the context of metastatic disease.
Table 1. (Continued.)
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tings in hormone-receptor–positive and HER2-
negative advanced breast cancer.13 In the open-
label, phase 2 PALOMA1 study involving patients 
who had not previously received endocrine ther-
apy and those with late relapses after adjuvant 
endocrine therapy, palbociclib in combination 
with letrozole resulted in longer progression-
free survival than letrozole alone.14 This finding 
suggests that palbociclib has activity when com-
bined with endocrine therapy in both patients 
who have not previously received endocrine 
therapy and those who have disease that is resis-
tant to such therapy. The ongoing PALOMA2 
study (ClinicalTrials.gov number, NCT01740427) 
is designed to further confirm the efficacy of 
palbociclib as a first-line treatment for patients 
who have not previously received endocrine 
therapy for their advanced disease. Other phase 3, 
Event
Palbociclib–Fulvestrant 
(N = 345)
Placebo–Fulvestrant 
(N = 172)
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
number of patients (percent)
Any adverse event 337 (97.7) 202 (58.6) 37 (10.7) 153 (89.0) 28 (16.3) 3 (1.7)
Neutropenia 272 (78.8) 184 (53.3) 30 (8.7) 6 (3.5) 0 1 (0.6)
Leukopenia 157 (45.5) 85 (24.6) 2 (0.6) 7 (4.1) 0 1 (0.6)
Fatigue 131 (38.0) 7 (2.0) 0 46 (26.7) 2 (1.2) 0
Nausea 100 (29.0) 0 0 45 (26.2) 1 (0.6) 0
Anemia 90 (26.1) 9 (2.6) 0 17 (9.9) 3 (1.7) 0
Headache 73 (21.2) 1 (0.3) 0 30 (17.4) 0 0
Thrombocytopenia 67 (19.4) 6 (1.7) 2 (0.6) 0 0 0
Upper respiratory 
infection†
67 (19.4) 1 (0.3) 0 28 (16.3) 0 0
Diarrhea 66 (19.1) 0 0 30 (17.4) 1 (0.6) 0
Constipation 58 (16.8) 0 0 24 (14.0) 0 0
Alopecia 51 (14.8)‡ NA NA 10 (5.8) NA NA
Hot flushes 51 (14.8) 0 0 28 (16.3) 0 0
Vomiting 50 (14.5) 1 (0.3) 0 21 (12.2) 1 (0.6) 0
Arthralgia 45 (13.0) 1 (0.3) 0 28 (16.3) 0 0
Cough 45 (13.0) 0 0 18 (10.5) 0 0
Decreased appetite 44 (12.8) 3 (0.9) 0 13 (7.6) 0 0
Stomatitis 40 (11.6) 2 (0.6) 0 4 (2.3) 0 0
Back pain 39 (11.3) 3 (0.9) 0 26 (15.1) 4 (2.3) 0
Dizziness 37 (10.7) 1 (0.3) 0 16 (9.3) 0 0
Dyspnea 37 (10.7) 0 1 (0.3) 11 (6.4) 1 (0.6) 0
Pain in extremity 34 (9.9) 0 0 19 (11.0) 3 (1.7) 0
*  Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA). Thromboembolic 
events occurred in less than 2% of patients in the palbociclib–fulvestrant group: two patients (0.6%) had a nonserious 
event, and four patients (1.2%) had a serious event (three pulmonary emboli and one deep-vein thrombosis). No 
thromboembolic adverse events were reported in the placebo–fulvestrant group. NA denotes not applicable.
†  Upper respiratory infection included influenza, influenza-like illness, laryngitis, nasopharyngitis or pharyngitis, rhinitis, 
sinusitis, and upper respiratory tract infection.
‡  A total of 13.6% of the patients in the palbociclib–fulvestrant group had grade 1 alopecia, whereas 1.2% had grade 2 
alopecia.
Table 2. Adverse Events with an Incidence of 10% or More in the Palbociclib–Fulvestrant Group, Regardless 
of Relationship to Study Drugs.*
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randomized studies are under way with the 
dual CDK4 and CDK6 inhibitors ribociclib 
(NCT01958021) and abemaciclib (NCT02246621). 
The PALOMA1 study had insufficient power to 
assess the effect of palbociclib on overall surviv-
al,14 and the number of deaths in the PALOMA3 
study at the time of the interim analysis was 
insufficient to assess overall survival. The effect 
of palbociclib on overall survival is unknown, 
and follow-up is ongoing.
Our results support the scientific evidence 
that the cyclin D1–CDK4–CDK6 dimer is a key 
downstream effector in hormone-receptor–posi-
tive breast cancer7 and remains so after the de-
velopment of resistance to endocrine therapy. 
Targeting CDK4 and CDK6 may represent a 
therapeutic strategy across diverse mechanisms 
of acquired resistance to endocrine therapy, in-
cluding activation of receptor tyrosine kinase 
signaling,18 up-regulation of PI3 kinase–mam-
malian target of rapamycin (mTOR) signaling,19 
and mutation of ESR1.20,21
The management of advanced hormone- 
receptor–positive disease has evolved, with several 
prospective studies indicating the importance of 
combining endocrine therapies with targeted 
drugs.2,14,22 Results observed with palbociclib 
compare favorably with those observed with 
other agents licensed for the treatment of post-
menopausal women in a similar population.2 
The median progression-free survival observed 
with placebo–fulvestrant in the PALOMA3 study 
was inferior to that in the prior studies of en-
docrine therapy alone,4 a finding that probably 
reflects the higher-risk, younger, and more 
heavily pretreated population recruited into the 
PALOMA3 study. Translational research efforts 
to identify markers of sensitivity or resistance to 
palbociclib in the PALOMA3 study are ongoing.
Guidelines and prior clinical studies suggest 
that premenopausal and perimenopausal pa-
tients with advanced cancer should be treated 
with ovarian suppression, either biochemically 
with gonadotropin-releasing hormone analogues 
or through surgical oophorectomy, and cared for 
as if they were postmenopausal patients.3,23-25 
Nevertheless, premenopausal patients are fre-
quently excluded from registration trials of cur-
rent targeted therapies given in combination 
with hormone therapy. The PALOMA3 study in-
cluded 108 premenopausal or perimenopausal 
patients in whom ovarian suppression was in-
duced by goserelin. The relative difference in 
progression-free survival between palbociclib 
and placebo was similar in premenopausal or 
perimenopausal patients and postmenopausal 
Figure 1. Progression-free Survival.
Panel A shows progression-free survival as assessed by the investigators in 
the intention-to-treat population (primary analysis), and Panel B shows 
progression-free survival according to central assessment in a random 
sample of patients by means of blinded, independent central review. NE 
denotes not estimable.
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patients, a finding that supports treatment 
guidelines and the inclusion of premenopausal 
or postmenopausal patients.
In conclusion, the PALOMA3 study showed 
that palbociclib with fulvestrant resulted in lon-
ger progression-free survival and a relatively 
higher quality of life than fulvestrant alone in 
patients with advanced hormone-receptor–posi-
tive breast cancer that had progressed during 
prior endocrine therapy, regardless of the pa-
tient’s menopausal status. Neutropenia was the 
most common adverse event in patients receiv-
ing palbociclib, but a very low incidence of fe-
brile neutropenia was observed in both treat-
ment groups.
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Figure 2. Subgroup Analysis of Progression-free Survival.
The blue boxes represent the hazard ratios with 95% confidence intervals (horizontal lines); the size of each box is proportional to the 
size of the corresponding subgroup. ER denotes estrogen receptor, and PR progesterone receptor.
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